Cerchietti Research Lab

Publications

Found 101 results
Journal Article
Brem EA, Li H, Beaven AW, Caimi PF, Cerchietti L, Alizadeh AA, Olin R, N Henry L, Dillon H, Little RF et al..  2022.  A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas . J Geriatr Oncol. 13(2):258-264.
Cerchietti LCA, Navigante AH, Körte MW, Cohen AM, Quiroga PN, Villaamil EC, Bonomi MR, Roth BM.  2003.  Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study.. Pain. 105(1-2):265-73.
Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H, B Ye H, Melnick A et al..  2011.  Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC.. Blood. 118(15):4174-8.
Zaitsev A, Chelushkin M, Dyikanov D, Cheremushkin I, Shpak B, Nomie K, Zyrin V, Nuzhdina E, Lozinsky Y, Zotova A et al..  2022.  Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes.. Cancer Cell. 40(8):879-894.e16.
Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, Ordoñez R, Cobaleda C, Botta C, Fresquet V et al..  2023.  Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.. Nat Med. 29(3):632-645.
Izzo F, Mercogliano F, Venturutti L, Tkach M, Inurrigarro G, Schillaci R, Cerchietti L, Elizalde PV, Proietti CJ.  2014.  Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.. Breast Cancer Res. 16(6):491.
Cerchietti LC, Lopes EC, Yang SNing, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L et al..  2009.  A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.. Nat Med. 15(12):1369-76.
Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang S-N, Cohen J et al..  2016.  Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.. J Clin Invest.
Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L et al..  2010.  Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.. Clin Lymphoma Myeloma Leuk. 10(3):192-6.
Ricker E, Verma A, Marullo R, Gupta S, Ye C, Pannellini T, Manni M, Tam W, Inghirami G, Elemento O et al..  2020.  Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma.. Sci Rep. 10(1):13094.
Dupont T, Yang SNing, Patel J, Hatzi K, Malik A, Tam W, Martin P, Leonard J, Melnick A, Cerchietti L.  2016.  Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.. Oncotarget. 7(3):3520-32.
Cerchietti LC, Polo JM, Da Silva GF, Farinha P, Shaknovich R, Gascoyne RD, Dowdy SF, Melnick A.  2008.  Sequential transcription factor targeting for diffuse large B-cell lymphomas.. Cancer Res. 68(9):3361-9.
Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, Bunting KL, Polo JM, Farès C, Arrowsmith CH et al..  2010.  A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.. Cancer Cell. 17(4):400-11.
Zahreddine HAhmad, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E et al..  2014.  The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.. Nature. 511(7507):90-3.
Polo JM, Dell'Oso T, Ranuncolo SMaris, Cerchietti L, Beck D, Da Silva GF, Prive GG, Licht JD, Melnick A.  2004.  Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.. Nat Med. 10(12):1329-35.
Ghetu AF, Corcoran CM, Cerchietti L, Bardwell VJ, Melnick A, Prive GG.  2008.  Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.. Mol Cell. 29(3):384-91.
Cerchietti L, Melnick A.  2013.  Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment? Expert Rev Hematol. 6(4):343-5.
Cerchietti L, Leonard JP.  2013.  Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP.. Hematology Am Soc Hematol Educ Program. 2013:591-5.
Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R et al..  2013.  Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.. Blood. 122(16):2837-47.
Boi M, Todaro M, Vurchio V, Yang SNing, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M et al..  2016.  Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.. Oncotarget. 7(48):79637-79653.
Marullo R, Rutherford SC, Leonard JP, Cerchietti L.  2016.  Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.. Cell Cycle. 15(17):2241-7.
Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, Phillip J, Pera B, Yang SNing, Takpradit K et al..  2017.  THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.. Nat Commun. 8:14290.
Walker SR, Liu S, Xiang M, Nicolais M, Hatzi K, Giannopoulou E, Elemento O, Cerchietti L, Melnick A, Frank DA.  2015.  The transcriptional modulator BCL6 as a molecular target for breast cancer therapy.. Oncogene. 34(9):1073-82.
Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, Shipp M, Melnick A.  2007.  Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.. Proc Natl Acad Sci U S A. 104(9):3207-12.
Li M, Teater MR, Hong JYoung, Park NR, Duy C, Shen H, Wang L, Chen Z, Cerchietti L, Davidson SM et al..  2022.  Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival.. Blood Cancer Discov. 3(1):50-65.